Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Lauren Fine

Dermatology Chicago, IL Medical Doctor

NPI 1790923241 CMS profile 36627

3000 N Halsted St Ste 701, Chicago, IL 60657

Open in the dashboard

General payments

$23,836

429 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Lauren Fine of Chicago, IL is reported in the CMS Open Payments database as having received $23,836 across 429 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 89th percentile of Dermatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $872 34
2024 General $3,730 52
2023 General $2,273 50
2022 General $1,458 62
2021 General $1,491 67
2020 General $1,388 46
2019 General $12,624 118

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Lauren Fine
  • Dermatology median
  • Middle half of Dermatology
  • National median

In program year 2025, general payments to Lauren Fine were reported at $872. Among 10,363 Dermatology profiles paid that year, the median was $788 and the middle half received between $207 and $1,974.

Show as a table
Year Lauren Fine Dermatology median Middle half National median
2019 $12,624 $454 $129–$1,240 $163
2020 $1,388 $235 $81–$756 $114
2021 $1,491 $377 $108–$1,108 $132
2022 $1,458 $514 $143–$1,391 $149
2023 $2,273 $607 $159–$1,674 $160
2024 $3,730 $751 $204–$1,903 $164
2025 $872 $788 $207–$1,974 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Merz North America, Inc. $10,137 32 payments
  2. AbbVie, Inc. $3,588 95 payments
  3. Allergan Inc. $3,080 21 payments
  4. Pfizer Inc. $819 53 payments
  5. Janssen Biotech, Inc. $738 34 payments
  6. Galderma Laboratories, L.P. $537 28 payments
  7. Chugai Pharmaceutical Co., Ltd. $525 1 payment
  8. Amgen Inc. $513 11 payments
  9. Genzyme Corporation $445 18 payments
  10. Sun Pharmaceutical Industries Inc. $444 24 payments
  11. Other $3,010 112 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $10,779 410 payments
  2. Travel and Lodging $8,049 9 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $2,500 2 payments
  4. Consulting Fee $2,325 4 payments
  5. Education $183 4 payments
Products named General payments · program years 2019–2025
  1. Xeomin $1,977 17 payments
  2. SKYRIZI $869 46 payments
  3. BOTOX COSMETIC $818 10 payments
  4. BOTOX $678 10 payments
  5. TREMFYA $669 25 payments
  6. HUMIRA $660 36 payments
  7. EUCRISA $590 42 payments
  8. CIBINQO $535 30 payments
  9. Otezla $513 11 payments
  10. DUPIXENT $397 15 payments
  11. Other $5,964 262 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 14 billing codes

Paid by Medicare

$5,468

Medicare's payments for the services billed

Medicare patients

25

Average age 69

Services billed

97

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 44%
Chronic kidney disease 0%
COPD 0%
Alzheimer's or dementia 0%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 17 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Xeomin
  • MERZ NORTH AMERICA, INC. $733
$733 — —
TREMFYA
  • Janssen Biotech, Inc. $152
$152 — —
Otezla
  • Amgen Inc. $141
$141 — —
DUPIXENT
  • Regeneron Healthcare Solutions, Inc. $58
  • GENZYME CORPORATION $23
$81 — —
RINVOQ
  • AbbVie, Inc. $69
$69 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 17 in the dashboard with a free account

Records

429 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Dermatology in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record